J Rhinol > Volume 31(2); 2024 |
|
Availability of Data and Material
All data generated or analyzed during the study are included in this published article and its supplementary information files.
Conflicts of Interest
Se Hwan Hwang and Do Hyun Kim who are on the editorial board of the Journal of Rhinology were not involved in the editorial evaluation or decision to publish this article. The remaining author has declared no conflicts of interest.
Author Contributions
Conceptualization: Se Hwan Hwang, Do Hyun Kim. Data curation: all authors. Formal analysis: Se Hwan Hwang. Funding acquisition: Se Hwan Hwang. Investigation: Se Hwan Hwang, Do Hyun Kim. Methodology: Do Hyun Kim. Project administration: Se Hwan Hwang, Do Hyun Kim. Resources: Se Hwan Hwang. Software: Se Hwan Hwang. Supervision: all authors. Validation: Se Hwan Hwang, Do Hyun Kim. Writing—original draft: Bo Yun Choi. Writing—review & editing: all authors.
Study | Study design | Number of patients | Age (yr) | Sex (male/female) | Nation | NAR/AR | Comparison | Device | Outcomes |
---|---|---|---|---|---|---|---|---|---|
Hwang 2017 [7] | Prospective cohort | 27 | 53.3±3.3 | 10/17 | USA | 14/13 | Pre-post | ClariFix device | Total nasal symptom score (regardless of AR or NAR subtype), TNSS subdomain, reflective TNSS (AR, NAR) |
Chang 2020 [4] | Prospective cohort | 98 | 58.6±16.2 | 35/63 | USA | 70/28 | Pre-post | ClariFix device | Total nasal symptom score (regardless of AR or NAR subtype), RQLQ, TNSS subdomain, reflective TNSS (AR, NAR) |
Yen 2020 [5] | Prospective cohort | 30 | 60.0±15.8 | 14/16 | USA | 14/16 | Pre-post | ClariFix device | Total nasal symptom score (regardless of AR or NAR subtype), RQLQ, TNSS subdomain |
Ow 2021 [8] | Prospective cohort (multicenter) | 62 | 57.1±13.4 | 22/40 | USA | 43/19 | Pre-post | ClariFix device | Total nasal symptom score (regardless of AR or NAR subtype) |
Gerka Stuyt 2021 [6] | Prospective cohort | 24 | 60.04±16.7 | 12/12 | USA | 16/8 | Pre-post | ClariFix device | Total nasal symptom score (regardless of AR or NAR subtype), TNSS subdomain, reflective TNSS (AR, NAR) |
Del Signore 2022 [3] | Randomized, single-blinded trial, sham-controlled (multicenter) | 133 | 55.2±16.3 | 77/56 | USA | 76/57 | Pre-post/comparison with sham | ClariFix device | Total nasal symptom score (regardless of AR or NAR subtype), RQLQ, TNSS subdomain, reflective TNSS (AR), comparison with sham control (respondent rate, TNSS, RQLQ) |
Rosi-Schumacher 2023 [9] | Prospective cohort | 127 | 52.4 (49.4–55.3) | 50/77 | USA | 64/63 | Pre-post | ClariFix device | Total nasal symptom score (regardless of AR or NAR subtype), RQLQ, TNSS subdomain |